At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D
BioAI的外部链接
1662 Elm St
US，New Hampshire，Manchester，03101
?? Exciting News ?? BioAI has been selected as a Top Innovator at the New England Venture Summit in Boston https://lnkd.in/enCPTkz4 ! Join us to meet our team or hear our CEO Tom Colarusso present the company and our AI biomarkers at the 1:50pm session on December 11th.
?? Exciting Announcement ?? For the first time, we will be presenting not one, but three posters at the Society for Immunotherapy of Cancer (SITC) conference this year. If you are planning to attend the conference next week, we would love to meet up or see you at one of our poster sessions. Use the link below to schedule a meeting with Thomas Colarusso and Alan Jerusalmi, PhD -- let's discuss how AI-powered pathology can accelerate your cancer research. https://lnkd.in/gS59fXGq
?? Excellent work ?? Our CIO,?Alan Jerusalmi, PhD,?has been busy this month! He will be at SITC next month?to discuss AI biomarkers and to present BioAI's recent work.
On behalf of BioAI, I am honored to have had the opportunity to present at the World Congress & Expo on Bioscience & Healthcare 2024 yesterday! This hybrid event brings together an inspiring group of global experts and innovators in healthcare, biosciences, and biotech. ? I had the privilege of sharing insights on Multi-modal AI for Translational Research & Precision Medicine, exploring how advanced AI technologies can drive breakthroughs in precision medicine and accelerate translational research to improve patient outcomes. ? It was a fantastic experience connecting with fellow professionals, learning from incredible thought leaders, and discussing the future of healthcare. A big thank you to the organizers for making this event such a success! Looking forward to continuing these important conversations. ? You can learn more about the conference and presenters using the link below: https://lnkd.in/eGgn5z_5
BioAI转发了
?? We are thrilled to announce strategic collaboration with BioAI in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). ?? We have also entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of ADCs and TCEs. The partnership supports multiple pipelines of about 10 first-in-class and best-in-class immunotherapeutics, including monoclonal, bispecific/biparatopic and TriAx antibodies within the coming 3 years. The collaboration will ensure Arbele continues to have at least 1-2 new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next 5 years without any technical and supply-chain interruptions. Read more in our press release below. https://lnkd.in/gPGWWR33 #AIoncology #PrecisionMedicine #Immunotherapeutics #Biotech #Diagnostics #CMC #ProcessDevelopment
?? Our recent partnership with Arbele was picked up by Precision Medicine Online! It's been an exciting week at BioAI ?? If you have a subscription, you can read the full story using the link below ?? https://lnkd.in/g97_pwf8
?? Exciting News ?? We are thrilled to announce a strategic partnership with Arbele to advance predictive AI models in oncology clinical trials. ?? This collaboration will harness BioAI's PredictX platform and Arbele’s clinical trial data to drive AI-powered biomarker screening for colorectal cancer (CRC). ?? The goal is to create cutting-edge companion diagnostic tests that enhance patient selection and treatment efficacy, revolutionizing personalized medicine for gastrointestinal cancers. ??? As our CEO, Thomas Colarusso, put it: "We are excited to apply our novel AI platform to accelerate the development of innovative treatment options for gastrointestinal cancers. This partnership underscores our commitment to transforming patient care through advanced machine learning." ?? Together, we are paving the way for precision medicine breakthroughs to help patients globally with high-mortality cancers. Learn more about this exciting partnership in the full article below! ??
???? Today is World Cancer Research Day – a day dedicated to raising awareness about the importance of cancer research and accelerating the fight against cancer. At BioAI, we aim to leverage the power of AI-driven precision biomarkers to transform precision medicine and improve patient outcomes. By harnessing cutting-edge technology, we strive to uncover innovative treatment pathways and enhance the quality of life for patients worldwide. Cancer research is not just about finding a cure—it's about finding better ways to detect, treat, and prevent cancer. As we continue to develop AI-powered solutions, we are proud to contribute to the global fight against cancer and collaborate with the scientific community to accelerate clinical R&D. Together, we can work toward a future where precision medicine transforms the lives of every cancer patient. #WorldCancerResearchDay #BioAI #PrecisionMedicine #CancerResearch #AIBiomarkers #CancerAwareness #Biotech
?? BioAI will be at the Bio-Trac? Spatial Biology Symposium next week in Germantown, MD and we hope to see some of you there! About the event: Esteemed experts from pathology, spatial biology, multiplex immunofluorescence, artificial intelligence, and translational medicine explore the latest advancements in the field. Focused on predictive and prognostic models, this gathering offers captivating presentations and insightful discussions.